Newer treatments of psoriasis regarding IL‐23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors

The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further research. Two drugs which are IL‐23 inhibitors...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Dermatologic therapy Ročník 30; číslo 6; s. e12555 - n/a
Hlavní autori:	Wcisło‐Dziadecka, Dominika, Zbiciak‐Nylec, Martyna, Brzezińska‐Wcisło, Ligia, Bebenek, Katarzyna, Kaźmierczak, Agata
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.11.2017
Predmet:	Animals biological drugs Cyclic Nucleotide Phosphodiesterases, Type 4 - immunology Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Humans IL‐23 inhibitors immune‐modulating Interleukin-23 Subunit p19 - antagonists & inhibitors Interleukin-23 Subunit p19 - immunology Interleukin-23 Subunit p19 - metabolism JAK inhibitors Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - therapeutic use Janus Kinases - antagonists & inhibitors Janus Kinases - metabolism Molecular Targeted Therapy PDE4 inhibitors Phosphodiesterase 4 Inhibitors - adverse effects Phosphodiesterase 4 Inhibitors - therapeutic use psoriasis Psoriasis - diagnosis Psoriasis - drug therapy Psoriasis - enzymology Psoriasis - immunology Signal Transduction - drug effects Skin - drug effects Skin - enzymology Skin - immunology Skin - pathology therapy treatment Treatment Outcome treatment PDE4 inhibitors psoriasis therapy biological drugs IL-23 inhibitors JAK inhibitors immune-modulating
ISSN:	1396-0296, 1529-8019, 1529-8019
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!